Dirk Aschmoneit
Director of Food & Retail MarketingJenny Craig, Inc
Dirk Aschmoneit is currently a Director of Marketing, Food & Retail at Jenny Craig - a division of Nestle Nutrition, where he has worked since 2004. He manages a $500 million group of food and non-food products. His duties include product development, assortment, merchandising for 500+ stores in the US & CAN, and maximizing revenue & profit growth. Mr. Aschmoneit directs overall strategy for food & non-food products to create a strategic competitive advantage and a calendar of supportive marketing efforts. Previously Mr. Aschmoneit was a Director of Marketing Operations at Metabolife International, from 1998 to 2004. He was instrumental in taking the company from a network marketing to a $355 million consumer packaged goods company. In addition to maintaining the company’s competitive position by evaluating new product concepts, Mr. Aschmoneit was frequently featured as an expert speaker at Sport, Weight Loss, and Condition Specific Supplement industry events. (This is me - Update Profile)
| 2004 - present | Director of Food & Retail Marketing Jenny Craig, Inc |
|---|---|
| 1998 - 2004 | Director of Marketing Operations METABOLIFE INTERNATIONAL INC |
GLG Study Groups with Dirk Aschmoneit(?)
| Study Group Name | Members |
|---|---|
| Media Buyers | 847 |
| Direct Mail Marketing Purchasers (North America) | 94 |
| Direct Mail Marketing Purchasers | 96 |
| Direct Mail Marketing Experts | 367 |
GLG NewsSM
Analyses by Dirk Aschmoneit(?)
Evaluation of NTRI Q3 performance: Q3 underperformance is not an indicator of a fad diet. Competition and lack of new campaign are primary drivers of recent performance. However, this might be an early indicator that NTRI is done with their steep growth phase and enters into the maturity phase with...
Glaxo Smith Kline is trying to reposition Xenical Here is a quick review of the past. It should be a solid indicator for the new initiative. Historical evolution of Alli: 1] GSK sales for Xenical $115.6 mil in 2004, down from $154.5 mil in 2002 2] Gastrointestinal side effects caused slow down...
After 3 years of impressive growth it might be time for a reality check for Nutrisystem (NTRI). The stock got “pounded” this week after NTRI issued a lower than expected guidance for Q107 and a Citigroup analyst lowered his target price by $13 (from $105 to $92). Is it time for bypass surgery...
GLG InstituteSM Seminars with Dirk Aschmoneit(?)
Recent Seminars
Request a project with Dirk Aschmoneit
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms

